(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

BACKGROUND: Paclitaxel has recently been reported by this laboratory to potentiate the high-LET radiation therapeutic (212)Pb-TCMC-trastuzumab, which targets HER2. To elucidate mechanisms associated with this therapy, targeted α-particle radiation therapeutic (212)Pb-TCMC-trastuzumab together with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, K J, Milenic, D E, Baidoo, K E, Brechbiel, M W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670476/
https://www.ncbi.nlm.nih.gov/pubmed/23632482
http://dx.doi.org/10.1038/bjc.2013.189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670476/
https://www.ncbi.nlm.nih.gov/pubmed/23632482
http://dx.doi.org/10.1038/bjc.2013.189

Ejemplares similares